BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Jun 18, 2019
Distillery Therapeutics

RLN2 injections to treat shoulder arthrofibrosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Injections of RLN2 could help treat shoulder arthrofibrosis, which manifests as long-standing restriction of joint range of motion. In a rat model of immobilization-induced shoulder arthrofibrosis, intra-articular injections of RLN2...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Small molecule HA inhibitor for treating H1, H5 flu infections

...Cell culture and mouse studies identified a small molecule HA inhibitor that could help treat H1...
...In canine cell-based infectivity assays, the compound inhibited infectivity of two H5 strains and five H1...
BioCentury | Mar 8, 2019
Preclinical News

Janssen, Scripps discover small molecule for flu

...have generated an oral compound for treating flu that inhibits the HA protein on influenza H1...
...potency and aqueous solubility to enable oral administration. The resulting compound, JNJ4796, blocked infection by H1...
...to a 100% survival rate and decreased weight loss. While the compound was effective against H1...
BioCentury | Feb 28, 2019
Company News

Akcea gains as Novartis exercises option for CV risk reduction therapy

Akcea Therapeutics Inc. (NASDAQ:AKCA) added $4.57 (17%) to $31.91 on Feb. 25 after Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option to license its antisense APOA1 inhibitor in a renewed attempt at CV risk reduction. Novartis...
BioCentury | Feb 25, 2019
Company News

Akcea gains as Novartis exercises option for CV risk reduction therapy

Akcea Therapeutics Inc. (NASDAQ:AKCA) added $4.57 (17%) to $31.91 on Monday after Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option to license its antisense APOA1 inhibitor in a renewed attempt at CV risk reduction. Novartis is...
BioCentury | Jan 11, 2019
Clinical News

Plinabulin meets in Phase III for chemotherapy-induced neutropenia

...N.Y. Product: Plinabulin (BPI-2358) Business: Hematology Molecular target: Tubulin; Guanine nucleotide exchange factor H1 (ARHGEF2; GEF-H1...
...Interim Phase III data Milestone: N/A Hongjiang Li plinabulin (BPI-2358, NPI-2358) BeyondSpring Inc. Guanine nucleotide exchange factor H1 (ARHGEF2) (GEF-H1) Tubulin...
BioCentury | Mar 16, 2018
Clinical News

Glenmark's Ryaltris meets in Phase III for seasonal allergic rhinitis

...of 25 μg mometasone furoate, an inhaled corticosteroid, and 665 μg olopatadine hydrochloride, a histamine H1...
...NSE:GLENMARK; BSE:532296), Mumbai, India Product: Ryaltris mometasone/olopatadine (formerly GSP 301) Business: Inflammation Molecular target: Histamine H1...
...Status: Phase III data Milestone: Submit NDA (1H18) Elizabeth S. Eaton Ryaltris, mometasone/olopatadine (gsp 301) Glenmark Pharmaceuticals Ltd. Histamine H1...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

...hematology Brain cancer; neutropenia; non-small cell lung cancer (NSCLC) Guanine nucleotide exchange factor H1 (ARHGEF2; GEF-H1...
BioCentury | Feb 22, 2018
Product R&D

Shooting for the universe

...head regions from rare flu viruses, such as H5, 7 or 8, fused to an H1...
Items per page:
1 - 10 of 297